Bristol-Myers Squibb Establishes Strategic Partnership With PAREXEL
PAREXEL International Corporation announced that Bristol-Myers Squibb, a global biopharmaceutical company, has established a strategic partnership with PAREXEL to enable greater effectiveness in clinical development. PAREXEL will work collaboratively with Bristol-Myers Squibb to provide strategic, operational and capability support of its clinical development program. PAREXEL’s approach to strategic partnering focuses on assisting biopharmaceutical companies in reducing fixed costs, shortening development times, and speeding delivery of safe and effective treatments to market.
PAREXEL will help provide global execution of Bristol-Myers Squibb’s clinical studies to support its full development pipeline over the next three years. The agreement with PAREXEL will complement Bristol-Myers Squibb’s internal capabilities, helping to meet the increasing needs of its pipeline with high-quality clinical development services.
“This partnership will increase the operational capability of our clinical development organization, and support our position in productivity and innovation,” said Brian Daniels, Senior Vice President, Global Development, Bristol-Myers Squibb. “Working with PAREXEL, Bristol-Myers Squibb will enhance support for our pipeline and improve our ability to deliver innovative medicines to patients with serious diseases.”
“We look forward to a deeply collaborative relationship with Bristol-Myers Squibb to help provide innovative solutions for its growing pipeline, as well as to leverage our global capabilities and worldwide technology infrastructure to support the effectiveness of its clinical development programs,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
